Trial Profile
A Phase 1/2a Evaluation of the Safety, Pharmacokinetics and Efficacy of AL3818, a Dual Receptor Tyrosine Kinase Inhibitor, in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary)
- Indications Adenocarcinoma; Carcinoma; Cervical cancer; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Advenchen Laboratories
- 17 Jun 2019 Status changed from recruiting to discontinued.
- 15 Jun 2017 Planned End Date changed from 1 Jun 2017 to 1 May 2018.
- 15 Jun 2017 Planned primary completion date changed from 1 May 2017 to 1 May 2018.